$60 Million

Bellerophon Therapeutics

Initial Public Offering

Bookrunner, February 2015

Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension.